• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

作者信息

Konstantinopoulos Panagiotis A, Cannistra Stephen A

机构信息

Dana-Farber Cancer Institute, Boston, MA.

Beth Israel Deaconess Medical Center, Boston, MA.

出版信息

J Clin Oncol. 2021 Jun 10;39(17):1833-1838. doi: 10.1200/JCO.21.00571. Epub 2021 Apr 23.

DOI:10.1200/JCO.21.00571
PMID:33891471
Abstract
摘要

相似文献

1
Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?卵巢癌中的免疫检查点抑制剂：我们能否弥合想象与现实之间的差距？
J Clin Oncol. 2021 Jun 10;39(17):1833-1838. doi: 10.1200/JCO.21.00571. Epub 2021 Apr 23.
2
Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.贝伐珠单抗、PARP 抑制剂和免疫检查点抑制剂在晚期卵巢癌一线治疗中的随机临床试验和真实世界前瞻性观察研究：一项关键性评价。
Anticancer Res. 2021 Oct;41(10):4673-4685. doi: 10.21873/anticanres.15281.
3
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.血清 CA-125 监测在接受免疫检查点抑制剂治疗的卵巢癌患者中的应用。
Gynecol Oncol. 2020 Aug;158(2):303-308. doi: 10.1016/j.ygyno.2020.04.710. Epub 2020 Jun 2.
4
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.阿维鲁单抗联合或不联合化疗序贯阿维鲁单抗维持治疗与单纯化疗用于未经治疗的上皮性卵巢癌患者（JAVELIN Ovarian 100）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Sep;22(9):1275-1289. doi: 10.1016/S1470-2045(21)00342-9. Epub 2021 Aug 4.
5
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.阿特珠单抗和 LncRNA PVT1 阻断协同通过 JAK2/STAT3/PD-L1 通路抑制顺铂耐药卵巢癌细胞的进展。
Clin Immunol. 2021 Jun;227:108728. doi: 10.1016/j.clim.2021.108728. Epub 2021 Apr 17.
6
Immune checkpoint inhibition: therapeutic implications in epithelial ovarian cancer.免疫检查点抑制：上皮性卵巢癌的治疗意义
Recent Pat Anticancer Drug Discov. 2015;10(2):133-44. doi: 10.2174/1574892810666150504121000.
7
Bibliometric and visual analysis of immune checkpoint inhibitors for ovarian cancer.卵巢癌免疫检查点抑制剂的文献计量学与可视化分析
Asian J Surg. 2024 Jul;47(7):3205-3206. doi: 10.1016/j.asjsur.2024.03.056. Epub 2024 Apr 10.
8
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.免疫检查点抑制剂在卵巢癌治疗中的新作用。
Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20.
9
Ophthalmic complications of immune checkpoint inhibitor therapy for metastatic ovarian cancer.转移性卵巢癌免疫检查点抑制剂治疗的眼科并发症
Can J Ophthalmol. 2022 Dec;57(6):e194. doi: 10.1016/j.jcjo.2022.02.020. Epub 2022 Mar 15.
10
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.随机 II 期试验：纳武利尤单抗对比纳武利尤单抗联合伊匹单抗用于复发性或持续性卵巢癌：NRG 肿瘤学研究。
J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10.

引用本文的文献

1
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.高级别浆液性卵巢癌的综合免疫基因组分析揭示了联合免疫疗法的潜在敏感性。
Front Immunol. 2024 Nov 28;15:1489235. doi: 10.3389/fimmu.2024.1489235. eCollection 2024.
2
Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma.铂类化疗可提高高级别浆液性卵巢癌患者单核细胞的抗原呈递潜能。
Front Immunol. 2024 Sep 9;15:1414716. doi: 10.3389/fimmu.2024.1414716. eCollection 2024.
3
Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
类器官在卵巢癌中的应用：疾病建模、精准医疗和药物评估的平台。
J Cancer Res Clin Oncol. 2024 Mar 20;150(3):146. doi: 10.1007/s00432-024-05654-0.
4
Siglec-9 tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer.Siglec-9 肿瘤相关巨噬细胞在高级别浆液性卵巢癌患者中划定了一个具有治疗脆弱性的免疫抑制亚群。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-007099.
5
Clinical and translational advances in ovarian cancer therapy.卵巢癌治疗的临床和转化进展。
Nat Cancer. 2023 Sep;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. Epub 2023 Aug 31.
6
Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies.用于改善免疫疗法临床前评估的人源化卵巢癌患者来源异种移植模型
Cancers (Basel). 2022 Jun 23;14(13):3092. doi: 10.3390/cancers14133092.
7
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype.卫星重复 RNA 在卵巢上皮性癌中的表达与肿瘤免疫抑制表型相关。
J Clin Invest. 2022 Aug 15;132(16). doi: 10.1172/JCI155931.
8
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.1809年至2022年及以后的卵巢癌研究视角
Diagnostics (Basel). 2022 Mar 24;12(4):791. doi: 10.3390/diagnostics12040791.
9
Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer.罗伊氏乳杆菌释放白介素-22（LR-IL-22）促进卵巢癌全腹照射（WAI）的肠道放射防护。
Radiat Res. 2022 Jul 1;198(1):89-105. doi: 10.1667/RADE-21-00224.1.
10
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.新辅助化疗后卵巢癌患者 T 细胞免疫增强。
Clin Cancer Res. 2022 Aug 2;28(15):3356-3366. doi: 10.1158/1078-0432.CCR-21-2834.